Literature DB >> 12467945

Eye movement disturbances in schizophrenia and a polymorphism of catechol-O-methyltransferase gene.

Janusz K Rybakowski1, Alina Borkowska, Piotr M Czerski, Joanna Hauser.   

Abstract

Previous studies suggested an association between the catechol-O-methyltransferase (COMT) Val/Met polymorphism and the performance on neuropsychological tests, measuring prefrontal function in schizophrenia. The aim of this study was to examine the relationship between this polymorphism and performance on oculomotoric tests in schizophrenic patients. The intensity of eye movement disturbances on fixation and smooth pursuit tests and the Val/Met polymorphism of COMT gene were studied in 117 schizophrenic patients (74 male and 43 female). In male schizophrenic patients, the mean intensity of both kinds of eye movement disturbances was lower in subjects who had the Met/Met genotype, with significant difference compared to other genotypes. Also, a significantly higher frequency of the Met allele and the Met/Met genotype was found in male schizophrenic patients exhibiting a lower intensity of smooth pursuit disturbances, and a trend in this direction was observed for the intensity of fixation disturbances. No such relationship was found in female schizophrenic patients. The results obtained suggest that, in male schizophrenic patients the Met allele of the COMT Val/Met polymorphism may have an alleviating effect on eye movement disturbances. They also point to possible gender differences as to the role of COMT in brain function in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12467945     DOI: 10.1016/s0165-1781(02)00245-7

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  13 in total

1.  Association of variants in DRD2 and GRM3 with motor and cognitive function in first-episode psychosis.

Authors:  Rebekka Lencer; Jeffrey R Bishop; Margret S H Harris; James L Reilly; Shitalben Patel; Rick Kittles; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-25       Impact factor: 5.270

Review 2.  Eye tracking dysfunction in schizophrenia: characterization and pathophysiology.

Authors:  Deborah L Levy; Anne B Sereno; Diane C Gooding; Gilllian A O'Driscoll
Journal:  Curr Top Behav Neurosci       Date:  2010

3.  Heritability and molecular genetic basis of antisaccade eye tracking error rate: a genome-wide association study.

Authors:  Uma Vaidyanathan; Stephen M Malone; Jennifer M Donnelly; Micah A Hammer; Michael B Miller; Matt McGue; William G Iacono
Journal:  Psychophysiology       Date:  2014-12       Impact factor: 4.016

Review 4.  The endophenotype concept in psychiatric genetics.

Authors:  Jonathan Flint; Marcus R Munafò
Journal:  Psychol Med       Date:  2006-09-18       Impact factor: 7.723

Review 5.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Authors:  Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

6.  Neuregulin-1 genotypes and eye movements in schizophrenia.

Authors:  H Magnus Haraldsson; Ulrich Ettinger; Brynja B Magnusdottir; Andres Ingason; Samuel B Hutton; Thordur Sigmundsson; Engilbert Sigurdsson; Hannes Petursson
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-03       Impact factor: 5.270

Review 7.  Approaches for unraveling the joint genetic determinants of schizophrenia and bipolar disorder.

Authors:  Ping-I Lin; Braxton D Mitchell
Journal:  Schizophr Bull       Date:  2008-05-22       Impact factor: 9.306

8.  Eye movement dysfunction in first-degree relatives of patients with schizophrenia: a meta-analytic evaluation of candidate endophenotypes.

Authors:  Monica E Calkins; William G Iacono; Deniz S Ones
Journal:  Brain Cogn       Date:  2008-10-18       Impact factor: 2.310

Review 9.  Which perspectives can endophenotypes and biological markers offer in the early recognition of schizophrenia?

Authors:  S Bender; M Weisbrod; F Resch
Journal:  J Neural Transm (Vienna)       Date:  2007-05-21       Impact factor: 3.575

Review 10.  Pharmacological treatment effects on eye movement control.

Authors:  James L Reilly; Rebekka Lencer; Jeffrey R Bishop; Sarah Keedy; John A Sweeney
Journal:  Brain Cogn       Date:  2008-12       Impact factor: 2.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.